American Society of Hematology, Blood Advances, 18(1), p. 1369-1381, 2017
DOI: 10.1182/bloodadvances.2017006825
Full text: Download
Key Points Germ line variants in ASXL1 and BIM are strong biomarkers of response to imatinib in chronic phase CML. A combined Sokal risk and ASXL1 and BIM variant model identified a subgroup of patients with the greatest risk of treatment failure.